Pulmonary Artery Denervation: Valid Alternative for Pulmonary Arterial Hypertension Grade 1?

Pulmonary vessels are densely innervated by sympathetic, parasympathetic, and sensitive fibers. 

denervación pulmonar

According to the World Health Organization (WHO) pulmonary arterial hypertension (PAH) grade 1 consists of obliterating pulmonary vascular remodeling accompanied by a diminished generation of vessel dilators.  

Its pharmacological treatment has certain limitations and sympathetic pulmonary vascular denervation might be a valid treatment alternative, seeing as it has shown promising results. 

128 patients with pulmonary hypertension grade 1 were randomized. Right cardiac catheterization was used to measure mean pulmonary pressure (25 mmHg), pulmonary vascular resistance (>3 U WOOD) and Wedge pressure (<15 mmHg) and negative vascular reactivity test. After this procedure, 63 patients received pulmonary denervation (PADN) plus optimal medical treatment and the remaining 65 simulated  renal denervation (SHAM procedure) plus optical medical treatment. 

Read also: How Do We Manage Antiaggregation in BARC I Bleeding after AMI?

Mean age was 40, they were mostly women, the most frequent cause was idiopathic, all patients were symptomatic and over 90% were in the low functional class. The 6-minute walk test was close to 400 meters and NT-proBNP was elevated, with no difference between the groups. Neither were there differences in treatment 30 days prior procedure. 

Mean pressure of the pulmonary artery was 53.9 mmHg and pulmonary vascular resistance was 10.9 U WOOD.

There were no complications during PADN or during the sham procedure. They all got optimal medical treatment at maximal doses with sildenafil or tadalafil.

At 6-month followup, even though both groups improved the 6 minute test walk, this resulted higher in patients receiving PADN vs the sham group, 50,9 vs 33,8 mts p=<0,00, as well as higher reduction of pulmonary vascular resistance-3 U WOOD vs. -1,9 U WOOD (adjusted difference 1.4; 95% CI: 2.6 to 0.2).

Read also: Mitral Trial: 2-Year Followup.

Also, PADN showed improved right ventricular function, lower tricuspid regurgitation and reduced NT-proBNP, as well as improved functional class and less clinical worsening. 

Conclusion

In patients with pulmonary hypertension grade 1 according to WHO, pulmonary denervation improves exercise capacity, hemodynamic state and clinical evolution at 6 months.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Original Title: Pulmonary Artery Denervation for Pulmonary Arterial Hypertension A Sham-Controlled Randomized PADN-CFDA Trial. 

Reference: Hang Zhan, et al. J Am Coll Cardiol Intv 2022;15:2412–2423.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...